Related Experiment Videos
Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors
1Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA. lopez@cop.ufl.edu
Insights
Statins effectively lower cholesterol for preventing and managing coronary artery disease (CAD). Despite proven benefits, many eligible patients remain undertreated, highlighting a need for wider application of these vital lipid-lowering agents.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Statins (HMG-CoA reductase inhibitors) significantly reduce total and LDL cholesterol.
- Large trials confirm statin efficacy in primary and secondary prevention of coronary artery disease (CAD).
Purpose of the Study:
- To review the current and future roles of statins in CAD prevention and management.
- To highlight the underutilization of statins in eligible patient populations.
- To explore potential expanded uses and necessary considerations for statin therapy.
Main Methods:
- Review of existing clinical trial data and treatment guidelines.
- Analysis of patient treatment patterns and adherence to cholesterol goals.
- Discussion of emerging therapeutic applications and safety considerations.
Main Results:
- Statins are highly effective in improving cardiovascular outcomes for high-risk individuals.
- A significant proportion of patients with CAD are untreated or inadequately treated with statins.
- Many high-risk patients are not achieving recommended cholesterol targets (NCEP).
- Populations like diabetics, women, the elderly, and those with existing CAD are at increased risk.
Conclusions:
- Statins are crucial for cardiovascular risk reduction but are frequently underused.
- Expanded use may include early hypercholesterolemia treatment and acute coronary syndromes.
- Management of atherosclerotic cerebrovascular disease is a potential future application.
- Pharmacists can play a key role in optimizing statin therapy and patient outcomes.
Abstract:
The current and future roles of statins as antilipemic agents for the prevention and management of coronary artery disease (CAD) are reviewed. Therapy with hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) substantially reduces total cholesterol and low-density-lipoprotein (LDL) cholesterol concentrations. Large clinical trials have documented the efficacy of statin therapy for both primary and secondary prevention of CAD. Nevertheless, many eligible patients are either untreated or inadequately treated with these agents. In one study, 61% of patients with documented CAD were not treated with a lipid-lowering agent. Large percentages of high-risk patients receiving such agents are not meeting cholesterol goals set by the National Cholesterol Education Program (NCEP). Populations at increased risk for coronary events include patients with diabetes, women, the elderly, and patients with established CAD. Comparative studies have not shown any one agent as clearly superior to the others. Future possibilities for statin use include early treatment of hypercholesterolemia and acute coronary syndromes consistent with guidelines established by NCEP. Many clinicians now believe that an aggressive approach to lowering LDL cholesterol may yield even greater reductions in coronary events. Treatment may reduce the risk of recurrent ischemic events when initiated within 96 hours of hospitalization for acute myocardial infarction or unstable angina and continued for up to four months. Another use may be the management of atherosclerotic cerebrovascular disease. Closer attention to potential adverse effects will be necessary before any expansion in statin use. Statins are highly effective for improving cardiovascular outcomes in high-risk patients but are frequently underused. Pharmacists can help extend the benefits of statins to more patients.